Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn’t offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to autism.
Finance
September 23, 2025
Kenvue stock rallies off record low after Trump press conference on alleged Tylenol-autism link
Advertisement
Related Articles
TruAlt Bioenergy shares list at 11% premium over …
TruAlt Bioenergy share price: TruAlt Bioenergy shares debuted with a premium on October 3 after …
9 hours, 42 minutes ago
1